Spinal Muscular Atrophy: Why a New Antisense Therapy is Moving to Phase 3 Trials
TouchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]
Our editorial board member and EAN Secretary General, Marianne de Visser (Academic Medical Centre, Amsterdam, The Netherlands), shares her expert insight into pregnancy and neuromuscular disorders. Questions 1. How does pregnancy affect the symptoms of neuromuscular disorders? (0:05) 2. What are the implications of neuromuscular disorders and their treatments for the development of the fetus […]
Following her lecture at EAN 2019 in Oslo, Dr. Tom Jenkins, EAN eCommunciations board member and incoming editor-in-chief of EANpages, spoke to Prof. Dame Pamela Shaw following her Moritz Romberg Lecture: Translational Neuroscience to improve outcomes for motor neuron disease. Are we winning? at EAN 2019. Video produced by and shared with kind authorisation of […]
Get the latest clinical insights from touchNEUROLOGY
